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Simple Summary: Tumors increase their glucose and choline uptake to support growth. These
properties are employed to detect and identify tumors in the body by imaging the uptake of radio-
isotope analogs of these compounds. In this study we show that deuterium metabolic imaging (DMI)
(a new MRI method to image metabolites using non-radioactive labeling with deuterium) can image
choline uptake in tumors. Furthermore, we demonstrate that DMI can image the tumor uptake
of choline and glucose (and additionally its metabolic conversion) simultaneously, in contrast to
radio-isotope imaging, which only assesses the uptake of one radio-isotope labeled compound at a
time. For these reasons (and also because DMI is relatively simple and can be combined with other
MR methods), it is a promising modality for a more specific tumor characterization than by separate
imaging of the uptake of radio-isotope labeled glucose or choline.
Abstract: Increased glucose and choline uptake are hallmarks of cancer. We investigated whether
the uptake and conversion of [2H9]choline alone and together with that of [6,6′-2H2]glucose can be
assessed in tumors via deuterium metabolic imaging (DMI) after administering these compounds.
Therefore, tumors with human renal carcinoma cells were grown subcutaneously in mice. Isoflurane
anesthetized mice were IV infused in the MR magnet for ~20 s with ~0.2 mL solutions containing
either [2H9]choline (0.05 g/kg) alone or together with [6,6′-2H2]glucose (1.3 g/kg). 2H MR was
performed on a 11.7T MR system with a home-built 2H/1H coil using a 90◦ excitation pulse and
400 ms repetition time. 3D DMI was recorded at high resolution (2 × 2 × 2 mm) in 37 min or at low
resolution (3.7 × 3.7 × 3.7 mm) in 2:24 min. Absolute tissue concentrations were calculated assuming
natural deuterated water [HOD] = 13.7 mM. Within 5 min after [2H9]choline infusion, its signal
appeared in tumor spectra representing a concentration increase to 0.3–1.2 mM, which then slowly
decreased or remained constant over 100 min. In plasma, [2H9]choline disappeared within 15 min
post-infusion, implying that its signal arises from tumor tissue and not from blood. After infusing a
mixture of [2H9]choline and [6,6′-2H2]glucose, their signals were observed separately in tumor 2H
spectra. Over time, the [2H9]choline signal broadened, possibly due to conversion to other choline
compounds, [[6,6′-2H2]glucose] declined, [HOD] increased and a lactate signal appeared, reflecting
glycolysis. Metabolic maps of 2H compounds, reconstructed from high resolution DMIs, showed
their spatial tumor accumulation. As choline infusion and glucose DMI is feasible in patients, their
simultaneous detection has clinical potential for tumor characterization.
Keywords: MRI; deuterium metabolic imaging; tumor; 2H; glucose; choline
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1. Introduction
Enhanced glucose uptake is a hallmark of malignant tumors. For diagnostic pur-
poses, this is traditionally assessed via PET using the glucose analog 18Fluordeoxyglucose
(FDG) [1]. However, this method cannot monitor subsequent glucose catabolism. For
in vivo applications, 13C magnetic resonance (MR) spectroscopy has been used to probe
uptake and metabolic conversions of non-radioactive 13C labeled glucose in tumors into
lactate and other compounds [2,3]. The low SNR of the method precludes its use as an
imaging method, although recently reported denoising methods may favor better imaging
conditions [4]. The hyper-polarization of 13C nuclei in labeled compounds considerably
improves the signal-to-noise ratio (SNR) of their signals. Applying these compounds to
the body enables imaging of metabolic processes otherwise not detectable by MR, but this
method is limited by a short time window of visibility. This short time window affects
glucose in particular due to short T1 relaxation times of the 13C nuclei in this molecule [5,6].
A further possibility for enhanced glucose detection in MR is provided by chemical ex-
change saturation transfer (CEST) imaging by which proton exchange between water and
glucose is employed to exploit the large magnetic pool of water protons for an SNR increase
in the detection of the glucose moiety. However, the method may be rather non-specific
due to various interactions in which these protons are involved and it also gives no direct
view on glucose catabolism [7].
Recently, the use of deuterium (2H or D) MR to trace deuterated metabolites in the
body (after administration of deuterated substrate) has gained new momentum under the
names of deuterium metabolic spectroscopy (DMS) or imaging (DMI), in particular for
the spatial monitoring of glucose uptake and its conversion in the brain and brain tumors
using non-radioactive [6,6′-2H2]glucose as substrate [8–10]. DMI has several advantages
(e.g., by tracking 2H in lactate and combined glutamine and glutamate signals, it provides
a quantitative biomarker for the Warburg effect [9] and for the glycolytic pathway in
tumors [11]). A potential clinical advantage of the method is the simplicity of its application
compared to FDG-PET and hyper-polarization MR [9].
Enhanced choline uptake is another hallmark of cancer and the uptake of choline com-
pounds in tumors has been assessed by 18F or 11C choline PET for diagnostic purposes [12].
Often, choline-PET identifies tumors better than FDG-PET [13,14]. Increased steady state
levels of choline compounds in tumors can be mapped by 1H MR spectroscopic imaging,
but separation of its different species is not possible [12,15]. The main different phosphory-
lated choline compounds can be detected via 31P MR spectroscopic imaging employing
1H decoupling or high magnetic fields (≥7T), although at a lower spatial resolution than
total choline detection via 1H MR spectroscopic imaging [12,16,17]. It is possible to obtain
choline in which the nine protons at the methyl groups are replaced by deuterons which is
favorable for a good SNR in DMI.
The aims of this study were to demonstrate the feasibility of DMI to monitor [2H9]
choline uptake in subcutaneous renal tumor models and to record the uptake and conver-
sion of [6,6′-2H2]glucose simultaneously with that of [2H9]choline in these tumors.
2. Materials and Methods
2.1. Tumors and Animal Handling
Animal experiments were conducted according to institutional guidelines and regula-
tions and were approved by the national Central Animal Experiments Committee (CCD)
and the local animal welfare body (RU-DEC-2017-0038-12 and RU-DEC-2017-0038-013).
Mice (age 6–8 weeks) were kept under specified pathogen free conditions and received
food and water ad libitum. Human renal carcinoma cells were subcutaneously injected
in the flank of athymic female BALB/c nu/nu mice (SKR17T-CA9-Luc cells) or of NSG
(NOD SCID) mice (NU12 cells) and tumors were grown up to about 0.5 cm3 in size. Before
the MR experiments, they were anesthetized by applying 1–2% isoflurane in a mixture
of O2/N2O = 1:2 through a mask. Respiration rate was maintained at 60–80 bpm. Body
temperature was monitored with a rectal probe and maintained at about 37 ◦C with heated
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air. A catheter was placed in a tail vein for the infusion of solutions with 2H compounds.
About 30 min before the MR measurement, mice were IM injected with 12 µg atropine
to prevent a possible cholinergic reaction of the choline bolus. At the time of the MR
experiments, the animals weighed 24–38 g.
2.2. MR Hardware and IV Infusions
Mice were placed prone in the small bore magnet of an 11.7T BioSpec Avance III animal
MR system (Bruker BioSpin GmbH, Ettlingen, Germany). The tumors were positioned
inside a circular 2H coil with 16 mm diameter (76.8 MHz), which was surrounded by a
circular 1H coil of 25 mm diameter (500.3 MHz).
Inside the magnet the mice were IV infused with a saline solution of ~0.2 mL in ~20 s
containing either 0.05 g/kg [2H9]choline or 0.05 g/kg [2H9]choline combined with 1.3 g/kg
[6,6′-2H2]glucose. The 2H compounds were obtained from Sigma-Aldrich (Zwijndrecht,
The Netherlands).
2.3. Deuterium MR Spectroscopy and Imaging
First, T2 weighted RARE 1H MR images were recorded with the 1H coil to check the
proper positioning of the tumors in the 2H coil (echo time (TE): 30 ms, repetition time (TR):
2500 ms, field of view (FOV): 20 × 20 mm, matrix 128 × 128 and a slice thickness (ST) of
1 mm) and T1 weighted 3D FLASH 1H MR images (TE: 2.3 ms; TR: 20 ms; flip angle: 10◦,
FOV: 33 × 33 × 33 mm; matrix 63 × 63 × 63) were acquired as reference images for the
DMI. Guided by the anatomical images, a volume of interest (VOI) of variable size (e.g.,
5 × 3 × 5 mm) was selected inside the tumor to optimize magnetic field homogeneity on
the line width of the water signal using a PRESS sequence.
DMS was recorded with a pulse-acquire sequence using a 50 µs square excitation
pulse of about 90◦ in the center of the coil. The pulse repetition time (TR) was 500 ms, the
acquisition band width was 14 ppm and 300 averages were acquired in a total acquisition
time of 2:24 min. 3D DMI was performed with a 1 ms composite RF pulse, optimized to
provide circa five-fold immunity towards RF inhomogeneity over a spectral bandwidth
>600 Hz, with TR = 400 ms and TE = 0.4 ms either at a high spatial resolution with a
FOV of 30 × 30 × 30 mm and matrix size 15 × 15 × 15 (resulting in nominal voxels
of 2 × 2 × 2 mm (8 µL) obtained in 37 min) or at low spatial resolution with a FOV of
33 × 33 × 33 and matrix size 9× 9× 9 (resulting in a nominal voxels of 3.7× 3.7× 3.7 mm
(~50 µL) recorded in 2:24 min). The k-space data were acquired with spherical sampling
in 3D.
2.4. Data Processing
Deuterium metabolic imaging data was handled in DMIWizard (Fourier transform,
phasing, filtering, image reconstruction), a home-written Matlab-based graphical user
interface for the processing of 1D DMS and 3D DMI data.
After FT of the time series of 45 FIDs, the 2H MR spectra were frequency aligned and,
to improve the SNR, a moving average of 3 spectra was applied using jMRUI software [18].
Within jMRUI, the program AMARES was used to fit the signals of deuterated water
(HOD), choline (Cho), glucose (Glc) and lactate (Lac), assuming a Lorentzian line shape.
The glucose signal was approximated with two Lorentzian shaped lines, resonating 4.6 Hz
apart. As additional prior knowledge in signal fitting, the relative resonance frequencies
of the signals were included relative to HOD at 4.8 ppm (i.e. Glc1 at 3.83 ppm, Glc2 at
3.77 ppm, Cho at 3.2 ppm and Lac at 1.3 ppm) and line widths were constrained between
10 and 60 Hz.
Absolute tissue concentrations were determined using the initial natural abundance
HOD signal as an internal reference assuming a natural abundance HOD concentration of
13.7 mM [8]. The tissue concentrations of compounds were normalized with respect to the
number of deuterons attached to them.
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2.5. Blood Samples
To determine 2H labeled compounds in blood, samples of 0.5 mL were obtained from
a puncture of the heart of the mice after infusion. Plasma was derived from the blood
samples by centrifugation for 5 min at 5000 rpm to separate it from cells. 2H NMR spectra
of 200 µL plasma samples were recorded at 500 MHz on a Bruker AVANCE III vertical bore
NMR system (Bruker BioSpin, Ettlingen, Germany) at a bandwidth of 12 ppm with 5 k
data points and 512 acquisitions. The repetition time was 5 s. If needed measurements per
time point were frequency aligned and averaged in jMRUI and for fitting AMARES was
applied using the same prior knowledge as for the in vivo spectra.
3. Results
DMS and DMI of Renal Tumor after [2H9]choline Infusion
To test if we could monitor the uptake of 2H9 choline in a subcutaneous tumor, we
infused 0.05 g/kg of a saline solution of about 0.15 mL of this compound for ~15 seconds
in the tail vein of mice carrying an SKRC17T tumor. On a T2 weighted MR image recorded
with the 1H coil, the tumor can be seen (Figure 1A). In a volume of 7 × 6 × 7 mm, the
magnetic field homogeneity in the tumor was optimized to a water line width of 65 Hz.
The 2H MR spectrum recorded with the 2H coil, without further localization, before the
infusion only showed a signal for natural abundance HOD (Figure 1B). Immediately
after the infusion a 2H signal appeared at ~3.2 ppm, well separated from that of HOD,
which is assigned to the deuterated methyl groups of choline compounds. From its signal
integral we deduced that its tissue concentration increased to a maximum level of ~1.2 mM
[2H9]choline at ~5 min post-infusion and then declined to 0.9 mM at ~15 min post-infusion,
after which it slowly decreased to ~0.7 mM at 100 min post-infusion (Figure 1D). Over this
time period, the HOD signal remained almost constant (Figure 1E) and no other resolved
2H signals were observed. Shortly after the infusion, the unfiltered line width of the
unlocalized signal was about 38 Hz for HOD and was about 25 Hz for [2H9]choline. In the
100 min thereafter, the linewidth of HOD did not change, but that of [2H9]choline steadily
increased to about 36 Hz (Figure 1F). From a high resolution 3D DMI obtained between
about 60 and 90 min post-infusion, a [2H9]choline map could be reconstructed (Figure 1C).
To test how well the 2H signals of [2H9]choline and of [6,6′-2H2]glucose are separated
we recorded 2H MR spectra of a phantom containing two tubes, one filled with [2H9]choline
and the other filled with [6,6′-2H2]glucose. An unlocalized 2H MR spectrum of the phantom
showed that the 2H signals of choline and glucose are well-resolved (Figure 2A). Using
a single Lorentzian line to fit these resonances resulted in a line width of 17.1 ± 4.2.Hz
(SD of fit error) for choline and 32.2 ± 4.3 Hz for glucose. The measurement of a 3D high
resolution DMI of the phantom enabled the reconstruction of separate maps for glucose
(Figure 2B) and choline (Figure 2C) in the tubes.
Subsequently, we investigated whether it was also possible to observe separated
choline and glucose signals in 2H spectra of a subcutaneous tumor by performing a 20 s
infusion of a solution with [2H9]choline and [6,6′-2H2]glucose in the tail vein of an NSG
mouse carrying a NU12-Luc-GFP tumor (Figure 2D) and recording a high resolution 3D
DMI. In a 2H MR spectrum of an 8 µL voxel in the DMI of the tumor, the deuterated
choline and glucose signals are well separated, and a resolved signal for deuterated lactate
is also observed (Figure 2E). The tissue concentration of [2H9]choline (averaged over the
time of the DMI recording of 37 min) was about 2 mM and its line width was 19 Hz. For
each of the deuterated compounds with signals in the 2H MR spectra, we reconstructed
metabolic maps parallel to the circular RF coil: HOD (Figure 2F), glucose (Figure 2G),
choline (Figure 2H), and lactate (Figure 2I). Although signal distribution in these maps is
also determined by the sensitive field of the RF coil, a comparison of the signal intensities
in the maps of the metabolites (which is expected to be the same if only determined by the
RF field) indicates differences in their distributions.
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Figure 1. Deuterium MR of a human renal tumor (SKRC17T) subcutaneously grown in a BALB/c mouse. (A). T2 MRI of the tumor. The chemical structure of [2H9]choline is also indicated.
(B). Unlocalized 2H MR spectra obtained with a surface coil at a time resolution of 2:30 min. The first spectrum recorded before the infusion of choline only shows a natural abundance
HOD signal at 4.8 ppm. Immediately after the infusion of a bolus of about 0.2 mL with [2H9]choline, a signal for this compound is observed at about 3.2 ppm. Within ~5 min after the
infusion this signal has reached its maximum value and then slowly declines over time. (C). A metabolic map of [2H9]choline reconstructed from a high resolution DMI obtained between
60 and 100 min post-infusion. (D). [2H9]choline tissue concentration (mM) as a function of time post-infusion. After a rapid initial increase, it slowly decreases over time. (E). HOD tissue
concentration (mM) as a function of time. Over the measurement period of 100 min the HOD concentration essentially remains constant. (F). Fitted linewidths (Hz) of the [2H9]choline and
HOD resonances as a function of time. That of HOD essentially remains constant, while that of [2H9]choline increases.
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Figure 2. Deuterium metabolic imaging study of deuterated glucose and choline in phantom and in a human renal tumor
subcutaneously growing in mice. (A). An unlocalized 2H MR spectrum of two tubes, one filled with a saline solution of 2H9
choline (63 mM) and the other with a saline solution of [6,6′-2H2]glucose (0.71 M). The glucose signal is completely separated
from the choline signal. (B). [6.6′-2H2]glucose map reconstructed from high resolution DMI of both tubes. (C). [2H9]choline
map reconstructed from high resolution DMI of both tubes. (D). T2 weighted MR image of a slice through a NU12 renal
carcinoma growing in the flank of an NSG mouse. A voxel of 8 µL is indicated, which was selected from a high resolution 3D
DMI recorded in 37 min after IV application of a mixture of [6,6′-2H2]glucose and [2H9]choline. (E). The 2H MR spectrum
of the 8 µL voxel selected from the tumor shows signals for water (HOD), glucose (Glc), choline (Cho) and lactate (Lac).
The spectrum was filtered with a 2Hz exponential line broadening. The glucose and choline signals are clearly separated.
(F). HOD map reconstructed from 3D DMI. (G). Glucose map reconstructed from 3D DMI. (H). Choline map reconstructed
from 3D DMI. (I). Lactate map reconstructed from 3D DMI. The maps are oriented parallel to the 2H RF coil (indicated by a
circle in F) and projected on top of T1 MR images. The metabolic color maps were scaled to the highest intensity of the
corresponding metabolite signal.
To examine if we can follow the conversion of [6,6′-2H2]glucose into lactate over time
in the presence of [2H9]choline in a tumor, we recorded sequential low spatial resolution
DMIs at a time resolution of 2:24 min after the infusion of a mixture of these compounds
into mice carrying a subcutaneous SKRC 17-CA9-Luc tumor (Figure 3A). A stack plot of
2H MR spectra and the calculated tissue concentrations of compounds in these spectra as a
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function of time are displayed in Figure 3B–F. The HOD level is steadily increasing over
time (Figure 3C), while the glucose content is increasing to a maximum concentration of
about 8 mM in 5–10 min and then declines (Figure 3D). During this decline, a signal at
1.3 ppm for lactate appeared (Figure 3E). The [2H9]choline tissue concentration increased
to values between 0.3 and 0.4 mM and remained stable up to 100 min. The line width of
the [2H9]choline signal increased from about 10 Hz immediately after infusion to about
15 Hz after 100 min.
Figure 3. Low spatial resolution 3D DMI (50 µL voxels), recorded at a time resolution of 2:24 min, from an SKRC 17T-CA9-
Luc tumor growing in the flank of a mouse. (A). T2 weighted MRI with a selected voxel inside the tumor indicated by a
red box. (B). Time series of 2H MR spectra consecutively recorded from this voxel over a period of 90 min showing an
increasing HOD signal, an increasing and decreasing glucose signal (C,D), a rapidly increasing and then constant choline
signal and a signal for lactate appearing during the decline of the glucose signal. (E,F). Time curves of metabolite tissue
concentrations (mM).
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Similar results were obtained in two other mice carrying tumors of the same batch. For
all 3 tumors the average tumor tissue concentration between 20 and 60 min post-infusion
was 0.32 ± 0.05 mM for [2H9]choline was 0.32 ± 0.05 mM and was 0.86 ± 0.27 mM for
deuterated lactate. The maximum average [6,6′-2H2]glucose tissue concentration at 10 min
post-infusion was 8.87 ± 2.58 mM. Initial linewidths of compound signals in the spectra
of all tumor DMIs, recorded shortly after the infusion, depended on the magnetic field
shimming results.
In 2H NMR spectra of blood plasma taken immediately after infusion of a mixture
of [6,6′-2H2]glucose and [2H9]choline, signals of both compounds can be detected next to
that of HOD (Figure 4A). Their concentrations were estimated to be 2.6 mM for choline
and 11.6 mM for glucose. From spectra taken at 15 min or longer after infusion, no choline
signal could be detected and the glucose signal was strongly decreased (Figure 4B). No
significant signal for [2H9]betaine (the first breakdown product of choline at ~3.4 ppm)
was detected.
Figure 4. 2H MR spectra recorded from plasma samples after infusion of a mixture of [6,6′-
2H2]glucose and [2H9]choline in mice carrying a subcutaneous renal tumor. (A). Spectrum taken
immediately after infusion. (B). Spectrum taken 15 min after infusion. The 2H signal for glucose is
strongly reduced and that for choline signal is absent. Vertical scales are arbitrary.
4. Discussion
In this study, we developed a protocol to follow the uptake and to image the presence
of [2H9]choline in renal tumors subcutaneously growing in the flank of mice via 2H MR
spectroscopy (DMS) and imaging (DMI) after an IV bolus administration of this compound.
In addition, we demonstrated that DMI can monitor the uptake of [2H9]choline in these
tumors simultaneously with that of [6,6′-2H2]glucose, and its conversion into lactate after
bolus administration of a mixture of both compounds. In 2H NMR spectra obtained of
blood plasma at 15 min post-infusion no [2H9]choline signal was present, in agreement
with the half-life of plasma choline of less than 1 min in mice [19]. This implies that the
[2H9]choline signal seen in the in vivo 2H MR spectra arises from tumor tissue.
Previously, the uptake of [2H9]choline has been monitored in an MCF7 human breast
tumor, growing subcutaneously in CD1 mice, via 2H MR spectroscopy at 4.7T of a single
voxel of 1 cm3 during continuous low dose infusion (16 µmol/kg/min) [20]. In contrast to
our study, a [2H9]choline signal only appeared ~40 min after the start of infusion, but then
increased to a tissue concentration of ~1.5 mM, which is comparable to the concentrations
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observed in our renal subcutaneous tumors (0.3–2 mM). During infusion, the plasma level
of [2H9]choline in CD1 mice reached a level of 222 ± 22 µM, while it was estimated in
our mice to be 2.6 mM immediately after the bolus application. The higher field strength
contributed to a better spectral resolution in our study, but also the smaller selected
volumes of 50 µL and 8 µL and possibly the tissue composition of the tumor favored an
improved field homogeneity and spectral resolution. Recently, the specific accumulation of
[2H9]choline in a tumor in the rat brain by DMI has been demonstrated [21].
In our experiments with only [2H9]choline infusion, the HOD signal did not change
much during the measurement time up to about 90 min, which is expected with a small
loss of deuterons from [2H9]choline or its downstream products in processes involving
exchange with water. With this protocol of bolus administration, we also did not detect
any signal for [2H9]betaine, the main breakdown product of choline compounds [22].
In all experiments with [2H9]choline infusion, its signal in tumors rapidly increased to
a maximum level within 5 min and then slowly decreased or remained stable up to 100 min
post-infusion. As we cannot discriminate among the choline species that contribute to
the [2H9]choline signal, it may be that the composition of these species change over time.
Recent 2H NMR studies of biopsies from brain tumors in the rat supplied with [2H9]choline
indicate that choline is metabolized into phosphocholine and glycerophosphocholine
within the tumor, although substantial amounts of free choline still seem to be present
after 36 min [23]. In this respect, it is interesting that in our experiments the line width of
the [2H9]choline signal increased over time, apparently because of the contribution of the
signals of other choline compounds with a slightly different chemical shift.
Because the IV application of a 0.05 g/kg [2H9]choline bolus may give an acute
cholinergic reaction [24], we applied atropine to the mice as preventive measure. To avoid
this application, the amount of [2H9]choline can be decreased and/or the infusion time can
be extended. In other supplementation studies (particularly in humans), choline is often
administered as a continuous infusion or orally [21,25,26].
Choline imaging with enhanced sensitivity has also been explored with hyperpolar-
ization by dynamic nuclear polarization (DNP) of [1,1,2,2 2H4, 1-13C] choline [27] and the
in vivo detection of DNP hyperpolarized 15N choline in the rat was demonstrated [28].
In these experiments, precautions also had to be taken to avoid cholinergic reactions be-
cause a bolus infusion with relatively high choline concentrations (~90 mM) was required.
The intrinsic sensitivity of MR experiments using hyperpolarization is much better than
that of 2H MR experiments. Although no one-to-one comparisons have been made yet,
we anticipate that this difference will be largely compensated by the much longer time
available for data acquisition in 2H MR experiments and the nine deuterons contributing
to the [2H9]choline signal. Apart from this sensitivity issue, 2H MR experiments are less
complicated to perform and easier to analyze than hyperpolarization MR experiments.
Increased steady state levels of choline compounds are a common finding in tumors
and are associated with demands for enhanced phospholipid metabolism to support
cellular membrane synthesis in oncogenesis and tumor progression. This property has
been explored in 1H MR spectroscopic imaging by using the (relative) intensity of the
overlapping signals of all choline compounds together as a non-invasive diagnostic marker
for several cancers such as in the brain, prostate and breast [12]. An increased total choline
signal may serve to localize the tumor and its quantified intensity to determine tumor stage
or aggressiveness [15] or to evaluate the effect of tumor treatments [29,30]. Choline tracer
imaging (such as in 11C choline PET or in [2H9]choline DMI) provides a more dynamic
view on choline uptake than the steady state levels of MRS detectable choline metabolites.
Although 1H MRSI offers a better spectral resolution than DMI, it faces the technical
challenge that the total choline signal has to be separated from background proton signals,
in particular of water and lipids. An even better spectral resolution is provided by 13C
MRS, but at the cost of a lower sensitivity, unless DNP methods are applied (vide supra).
In this feasibility study we noticed that tumors may accumulate different levels
of [2H9]choline and with variable spatial distributions. In future studies this has to be
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correlated with molecular features of these tumors such as proliferation markers, glucose
and choline transporters, and with tumor heterogeneity. In addition, the value of our DMI
approaches should be tested in tumors of different origin and body location.
The simultaneous monitoring by DMI of the uptake of choline and glucose and its
conversion over time, after combined [6,6′-2H2]glucose and [2H9]choline infusion, was
demonstrated for renal SKRC 17-CA9-Luc tumors. The concentration-time curve of [6,6′-
2H2]glucose recorded for these tumors are comparable to that in subcutaneously growing
EL4 tumors recorded under similar infusion and DMI conditions, taking normalization
with initial [HOD] into account [11]. However, the deuterated lactate concentration in
our tumors was much lower, which indicates more oxidative metabolism or rapid lactate
processing. As no metabolites related to the TCA cycle have been detected (e.g., glutamate),
it is likely that lactate processing or removal is more efficient in these renal tumors.
To apply DMI of choline and glucose, separately or combined, to humans at lower
field strengths (≤7T), it is necessary that their signals are resolved from HOD and from
each other. The line width of HOD from DMI volumes in the tumor (15–25 Hz) was larger
than that reported for the human brain at 4 and 7T [31], which is likely due to more difficult
magnetic field shimming conditions. For choline, we found line widths of about 10 to
20 Hz. As the spectral separation between HOD and choline signals is ~1.5 ppm, which
translates to ~30 Hz difference at 3T, and assuming no field dependent change in line
width [31], it follows that these signals can also be separately observed at this clinical field
strength. Likewise, we anticipate that glucose and choline signals (~0.5 ppm apart) can
be distinguished at 7T, but at 3T this may more critically depend on shimming results.
However, the glucose signal disappears within ~60 min post-infusion, which would allow
the observation of the choline signal as its intensity then has not changed much yet.
FDG PET is widely employed to detect tumors in the human body and 11C or 18F
choline PET is applied in more specific cases (such as in the characterization of prostate
and other cancers in the body [14,32,33]). Because of the high sensitivity of PET, isotope
labeled compounds can be applied at trace amounts, but when endogenous compounds
occurring at high body concentration are involved (e.g., glucose and choline), DMI may
be considered as a non-radioactive alternative. This has several additional advantages,
such as that these compounds can be monitored simultaneously, that the metabolism of
glucose to lactate and other compounds and to HOD can be evaluated and that it can be
combined with multi-parametric MRI. The application of other combinations of deuterated
compounds in tumor studies are foreseeable, as long as their signals are spectrally resolved,
for instance choline with the conversion of fumarate into malate to assess tumor cell death
after treatments [34] or an inert deuterated compound to assess tumor perfusion.
DMI does require that MR machines are equipped with dedicated 2H RF coils. For
humans, RF coils of sufficient quality for DMI at 7T to diagnose tumors in the brain have
been presented that appear to offer a spatial resolution comparable to that of FDG PET [9].
Recently, dedicated human 2H body coils were also shown to be able to record DMIs, such
as those of the liver after [6,6′-2H2]glucose application [9,35]. However, it remains to be
seen what spatial resolution and tissue coverage can be achieved to detect and characterize
tumors in the body as compared to FDG and choline PET, which essentially provide
whole body imaging. The SNR of DMI experiments can be improved by signal denoising,
as recently demonstrated for DMI at 3T [36], and also by more optimal MR detection
methods [37], which can be employed for better spatial resolution or faster imaging.
5. Conclusions
In this study, we demonstrate that DMI of [2H9]choline uptake in tumors subcu-
taneously growing in the mice is feasible. Moreover, we show that the simultaneous
monitoring of [2H9]choline and [6,6′-2H2]glucose and its catabolic product lactate in tu-
mors via DMI is possible. This enables researchers to obtain information from two main
tumor properties at the same time, enhanced glucose uptake and catabolism and choline
uptake, and therefore has the potential to provide a more specific metabolic characteri-
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zation of tumor lesions than that obtained with single tracer, single parameter metabolic
imaging.
As DMI of glucose uptake and its metabolic conversions is feasible in patients, the
simultaneous performance of choline and glucose DMI has clinical potential.
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